Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Jairia Dela Cruz, 27 Mar 2020
Use of antioxidants for treating male factor infertility appears to be of little benefit, improving neither semen parameters nor DNA integrity, according to the results of the Males, Antioxidants and Infertility (MOXI) trial.

Treating vitamin D deficiency may help prevent COPD attacks

Pearl Toh
16 Feb 2019

Vitamin D supplements can help reduce the rate of moderate-to-severe COPD* exacerbations in patients with inadequate vitamin D levels (<25 nmol/L) at baseline, but not in those with higher levels, according to a meta-analysis of randomized controlled trials (RCTs).  

“Vitamin D supplementation is safe, and it costs just a few pence to supplement a person for a year - so this is a potentially highly cost-effective treatment that could be targeted at those who have low vitamin D levels following routine testing,” suggested principal investigator Professor Adrian Martineau from Queen Mary University of London in London, UK.

The meta-analysis used individual participant data from three double-blind RCTs involving 469 patients with COPD who were randomized to either oral vitamin D3 supplementation or placebo. [Thorax 2019;doi10.1136/thoraxjnl-2018-212092] 

In the overall study population, supplemental vitamin D had no effects on the rate of moderate/severe COPD exacerbations compared with placebo (adjusted incidence rate ratio [aIRR], 0.94; p=0.52).

However, subgroup analysis revealed that supplemental vitamin D benefits patients with baseline 25-hydroxyvitamin D levels <25 nmol/L, who saw the rates of moderate/severe COPD exacerbations significantly reduced by almost half (aIRR, 0.55; p=0.006).

In contrast, the protective effects were not seen in the patient subgroup whose baseline 25-hydroxyvitamin D [25(OH)D] levels were 25 nmol/L (aIRR, 1.04; p=0.71).

“Our study shows that giving supplements to vitamin D-deficient COPD patients nearly halves their rate of potentially fatal attacks,” said Martineau.

“Given the high prevalence of profound vitamin D deficiency in people with COPD, and the large reduction in exacerbation rates seen with vitamin D supplementation in [the subgroup with low baseline 25(OH)D], our findings support a strategy of routinely testing vitamin D status in patients with COPD who experience exacerbations and offering supplementation to [these patients],” the researchers stated.

There was no effect on COPD exacerbations with vitamin D supplementation when the analyses were prespecified by other factors such as baseline GOLD spirometric grade, BMI, concomitant use of inhaled corticosteroids, polymorphisms in genes involved in vitamin D metabolism (VDR and DBP), and the frequency of vitamin D dosing.

The proportion of patients who had at least one serious adverse event also did not change with vitamin D supplementation (adjusted odds ratio, 1.16, 95 percent confidence interval, 0.76–1.75), which according to the researchers, indicates that “vitamin D supplementation was safe at the doses administered.”

“Serious adverse events and occasional episodes of hypercalcaemia were evenly distributed between participants randomized to vitamin D versus placebo, and no instances of renal stones were seen,” they noted.

The findings echoed the results from previous studies by the same research team, which showed that vitamin D supplementation was protective against asthma attacks and acute respiratory infections in people with low baseline vitamin D levels. [BMJ 2017;356:i6583; Lancet Respir Med 2017;5:881-890]

“Since acute respiratory infections commonly precipitate exacerbations of both asthma and COPD, it may be that protective effects of vitamin D against these outcomes are mediated by a common mechanism, namely induction of antiviral and antimicrobial responses,” suggested Martineau and co-authors on the potential mechanism behind the protective effects of vitamin D. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Jairia Dela Cruz, 27 Mar 2020
Use of antioxidants for treating male factor infertility appears to be of little benefit, improving neither semen parameters nor DNA integrity, according to the results of the Males, Antioxidants and Infertility (MOXI) trial.